All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
XS-0622-ZP3223 | Anti-LAG3 h(VHH1-VHH2-CD28-CD3ζ) Biepitopic CAR, pCDCAR1 | Human | VHH1-VHH2-CD28-CD3ζ | Lentiviral vector | T Cell | ||||
XS-0622-ZP3395 | Anti-LAG3 h(VHH1-VHH2-4-1BB-CD3ζ) Biepitopic CAR, pCDCAR1 | VHH1-VHH2-4-1BB-CD3ζ | Lentiviral vector | T Cell | |||||
XS-0822-YF607 | Anti-Human LAG3 (XW-607) h(41BB-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-607 | Mouse | scFv-41BB-CD3ζ | In Vitro Transcription (IVT) Vector | |||
XS-0822-YF608 | Anti-Human LAG3 (XW-608) h(41BB-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-608 | Mouse | scFv-41BB-CD3ζ | In Vitro Transcription (IVT) Vector | |||
XS-0822-YF609 | Anti-Human LAG3 (XW-609) h(41BB-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-609 | Human | scFv-41BB-CD3ζ | In Vitro Transcription (IVT) Vector | |||
XS-0822-YF610 | Anti-Human LAG3 (XW-610) h(41BB-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-610 | Humanized | scFv-41BB-CD3ζ | In Vitro Transcription (IVT) Vector | |||
XS-0822-YF611 | Anti-Mouse LAG3 (XW-611) m(41BB-CD3ζ) CAR IVT Plasmid, pCARIVT | Mouse | XW-611 | Human | scFv-41BB-CD3ζ | In Vitro Transcription (IVT) Vector | |||
XS-0822-YF612 | Anti-Mouse LAG3 (XW-612) m(41BB-CD3ζ) CAR IVT Plasmid, pCARIVT | Mouse | XW-612 | Humanized | scFv-41BB-CD3ζ | In Vitro Transcription (IVT) Vector | |||
XS-0822-YF1527 | Anti-Human LAG3 (XW-607) h(CD28-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-607 | Mouse | scFv-CD28-CD3ζ | In Vitro Transcription (IVT) Vector | |||
XS-0822-YF1528 | Anti-Human LAG3 (XW-608) h(CD28-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-608 | Mouse | scFv-CD28-CD3ζ | In Vitro Transcription (IVT) Vector | |||
XS-0822-YF1529 | Anti-Human LAG3 (XW-609) h(CD28-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-609 | Human | scFv-CD28-CD3ζ | In Vitro Transcription (IVT) Vector | |||
XS-0822-YF1530 | Anti-Human LAG3 (XW-610) h(CD28-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-610 | Humanized | scFv-CD28-CD3ζ | In Vitro Transcription (IVT) Vector | |||
XS-0822-YF1531 | Anti-Mouse LAG3 (XW-611) m(CD28-CD3ζ) CAR IVT Plasmid, pCARIVT | Mouse | XW-611 | Human | scFv-CD28-CD3ζ | In Vitro Transcription (IVT) Vector | |||
XS-0822-YF1532 | Anti-Mouse LAG3 (XW-612) m(CD28-CD3ζ) CAR IVT Plasmid, pCARIVT | Mouse | XW-612 | Humanized | scFv-CD28-CD3ζ | In Vitro Transcription (IVT) Vector | |||
XS-0822-YF2447 | Anti-Human LAG3 (XW-607) h(CD28-41BB-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-607 | Mouse | scFv-CD28-41BB-CD3ζ | In Vitro Transcription (IVT) Vector | |||
XS-0822-YF2448 | Anti-Human LAG3 (XW-608) h(CD28-41BB-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-608 | Mouse | scFv-CD28-41BB-CD3ζ | In Vitro Transcription (IVT) Vector | |||
XS-0822-YF2449 | Anti-Human LAG3 (XW-609) h(CD28-41BB-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-609 | Human | scFv-CD28-41BB-CD3ζ | In Vitro Transcription (IVT) Vector | |||
XS-0822-YF2450 | Anti-Human LAG3 (XW-610) h(CD28-41BB-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-610 | Humanized | scFv-CD28-41BB-CD3ζ | In Vitro Transcription (IVT) Vector | |||
XS-0822-YF2451 | Anti-Mouse LAG3 (XW-611) m(CD28-41BB-CD3ζ) CAR IVT Plasmid, pCARIVT | Mouse | XW-611 | Human | scFv-CD28-41BB-CD3ζ | In Vitro Transcription (IVT) Vector | |||
XS-0822-YF2452 | Anti-Mouse LAG3 (XW-612) m(CD28-41BB-CD3ζ) CAR IVT Plasmid, pCARIVT | Mouse | XW-612 | Humanized | scFv-CD28-41BB-CD3ζ | In Vitro Transcription (IVT) Vector |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION